Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001 + STK-009) in Subjects With Relapsed or Refractory CD19+ Hematologic Malignancies

NCT05665062 is registered in ClinicalTrials.gov with Synthekine as lead sponsor.

NCT NCT05665062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05665062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001 + STK-009) in Subjects With Relapsed or Refractory CD19+ Hematologic Malignancies
Lead sponsor
Synthekine
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 23, 2023
Completion date
November 30, 2041
Enrollment
36 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cll/sll, diffuse large b cell lymphoma, follicular lymphoma, indolent b-cell non-hodgkin lymphoma, large b-cell lymphoma, mantle cell lymphoma, nhl